Pralsetinib

普拉替尼

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NamePralsetinib
Drug Alias NamePratinibGAVRETOGavreto普吉华Pujihua +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursThyroid Diseases +[36] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2020/09/04
Country/TerritoryBelgiumPanamaUnited States +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBlueprint Medicines Corp
China Registration ClassN/A

Develop Information

Active CompaniesRigel PharmaceuticalsF. Hoffmann-La Roche AgF. Hoffmann-La Roche Ltd +[10] 
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursThyroid Diseases +[31] 
Inactive IndicationsEndocrine System DiseasesBronchial DiseasesRespiratory Tract Diseases +[5] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG